Insider Screener
Real-time Form 4 Filtering Engine
| Filing Date | Trade Date | Ticker | Company Name | Reporting Person | Relationship | Industry (by SEC) | Type | Price | Qty | Total, $ | Owned After | Change, % |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-06-10 15:19 | 2026-06-05 | MGX | Metagenomi Therapeutics, Inc. | Wein Matthew | Officer; See Remarks | Biological Products, (No Diagnostic Substances) | SALE | $1.30 | 558 | $725 | 126,491 | -0.4% |
| 2026-06-10 15:21 | 2026-06-05 | MGX | Metagenomi Therapeutics, Inc. | Irish Jian | Director, Officer; See Remarks | Biological Products, (No Diagnostic Substances) | SALE | $1.30 | 3,737 | $4,854 | 377,533 | -1.0% |
| 2026-06-10 15:23 | 2026-06-05 | MGX | Metagenomi Therapeutics, Inc. | Wapnick Pamela | Officer; Chief Financial Officer | Biological Products, (No Diagnostic Substances) | SALE | $1.30 | 2,884 | $3,746 | 208,491 | -1.4% |
| 2026-06-10 10:04 | 2026-06-08 | INDV | Indivior Pharmaceuticals, Inc. | Preblick Ryan | Officer; Chief Financial Officer | Pharmaceutical Preparations | SALE | $37.70 | 36,000 | $1,357,200 | 284,751 | -11.2% |
| 2026-06-09 20:10 | 2026-06-08 | IPSC | Century Therapeutics, Inc. | Russotti Gregory | Officer; See Remarks | Biological Products, (No Diagnostic Substances) | SALE | $2.11 | 524 | $1,106 | 514,903 | -0.1% |
| 2026-06-09 20:10 | 2026-06-08 | IPSC | Century Therapeutics, Inc. | Carr Douglas | Officer; SVP Finance & Operations | Biological Products, (No Diagnostic Substances) | SALE | $2.11 | 249 | $526 | 506,748 | 0.0% |
| 2026-06-09 20:20 | 2026-06-08 | MYGN | MYRIAD GENETICS INC | Kumar Rashmi | Director | In Vitro & In Vivo Diagnostic Substances | SALE | $4.46 | 15,000 | $66,843 | 171,889 | -8.0% |
| 2026-06-09 20:05 | 2026-06-05 | ACOG | Alpha Cognition Inc. | Opaleye Management Inc. | 10% owner | Biological Products, (No Diagnostic Substances) | BUY | $5.83 | 10,054 | $58,596 | 2,614,161 | +0.4% |
| 2026-06-09 21:06 | 2026-06-08 | DYN | Dyne Therapeutics, Inc. | Posner Brian S | Director | Pharmaceutical Preparations | BUY | $16.94 | 2,000 | $33,880 | 24,500 | +8.9% |
| 2026-06-09 20:53 | 2026-06-05 | AWHL | Aspira Women's Health Inc. | SCHULER JACK W | 10% owner | In Vitro & In Vivo Diagnostic Substances | BUY | $0.45 | 222,222 | $100,000 | 4,046,051 | +5.8% |
| 2026-06-10 01:21 | 2026-06-08 | MIRM | Mirum Pharmaceuticals, Inc. | BJERKHOLT ERIC | Officer; CHIEF FINANCIAL OFFICER | Pharmaceutical Preparations | OPT+S | $93.82 | 5,000 | $469,077 | 44,788 | -10.0% |
| 2026-06-10 00:32 | 2026-06-08 | ABEO | ABEONA THERAPEUTICS INC. | Seshadri Vishwas | Director, Officer; Chief Executive Officer | Pharmaceutical Preparations | SALE | $5.36 | 56,344 | $301,919 | 1,374,079 | -3.9% |
| 2026-06-10 00:32 | 2026-06-08 | ABEO | ABEONA THERAPEUTICS INC. | Vasanthavada Madhav | Officer; Chief Commercial Officer | Pharmaceutical Preparations | SALE | $5.36 | 9,620 | $51,549 | 303,451 | -3.1% |
| 2026-06-10 00:32 | 2026-06-08 | ABEO | ABEONA THERAPEUTICS INC. | Vazzano Joseph Walter | Officer; Chief Financial Officer | Pharmaceutical Preparations | SALE | $5.38 | 49,338 | $265,241 | 518,437 | -8.7% |
| 2026-06-10 00:32 | 2026-06-08 | ABEO | ABEONA THERAPEUTICS INC. | O'Malley Brendan M. | Officer; SVP, Chief Legal Officer | Pharmaceutical Preparations | SALE | $5.36 | 11,131 | $59,645 | 440,003 | -2.5% |
| 2026-06-09 22:33 | 2026-06-05 | ANIP | ANI PHARMACEUTICALS INC | CAREY STEPHEN P. | Officer; SVP & CFO | Pharmaceutical Preparations | OPT+S | $80.00 | 3,312 | $264,960 | 180,393 | -1.8% |
| 2026-06-09 22:06 | 2026-06-08 | UTHR | UNITED THERAPEUTICS Corp | EDGEMOND JAMES | Officer; CFO AND TREASURER | Pharmaceutical Preparations | OPT+S | $547.50 | 10,000 | $5,475,045 | 18,876 | -34.6% |
| 2026-06-09 21:37 | 2026-06-09 | BCDA | BioCardia, Inc. | Altman Peter | Director, Officer; President and CEO | Biological Products, (No Diagnostic Substances) | BUY | $0.85 | 5,000 | $4,250 | 298,266 | +1.7% |
| 2026-06-09 21:40 | 2026-06-09 | CYTK | CYTOKINETICS INC | Malik Fady Ibraham | Officer; EVP Research & Development | Pharmaceutical Preparations | OPT+S | $67.98 | 3,500 | $237,930 | 153,902 | -2.2% |
| 2026-06-09 21:40 | 2026-06-05 | IMNM | Immunome Inc. | BIENAIME JEAN JACQUES | Director | Pharmaceutical Preparations | BUY | $19.45 | 10,500 | $204,260 | 43,415 | +31.9% |
| 2026-06-09 21:40 | 2026-06-05 | IMNM | Immunome Inc. | BIENAIME JEAN JACQUES | Director | Pharmaceutical Preparations | SALE | $19.41 | 10,500 | $203,820 | 32,915 | -24.2% |
| 2026-06-09 21:40 | 2026-06-05 | NBIX | NEUROCRINE BIOSCIENCES INC | SHERWIN STEPHEN A | Director | Biological Products, (No Diagnostic Substances) | OPT+S | $165.32 | 25,000 | $4,132,970 | 15,860 | -61.2% |
| 2026-06-09 21:30 | 2026-06-09 | TNXP | Tonix Pharmaceuticals Holding Corp. | LEDERMAN SETH | Director, Officer; Chief Executive Officer | Pharmaceutical Preparations | BUY | $11.79 | 5,000 | $58,950 | 9,005 | +124.8% |
| 2026-06-09 21:30 | 2026-06-08 | TNXP | Tonix Pharmaceuticals Holding Corp. | Stillwell Richard Newcomb | Director | Pharmaceutical Preparations | BUY | $11.65 | 5,000 | $58,250 | 5,000 | +100.0% |
| 2026-06-09 21:17 | 2026-06-09 | AXSM | Axsome Therapeutics, Inc. | Pizzie Nick | Officer; Chief Financial Officer | Pharmaceutical Preparations | OPT+S | $240.09 | 33,000 | $7,922,970 | 42,867 | -43.5% |
| 2026-06-09 21:17 | 2026-06-09 | AXSM | Axsome Therapeutics, Inc. | TABUTEAU HERRIOT | Director, Officer, 10% owner; Chief Executive Officer | Pharmaceutical Preparations | OPT+S | $241.01 | 49,670 | $11,970,967 | 7,229 | -87.3% |
| 2026-06-09 20:48 | 2026-06-08 | UTHR | UNITED THERAPEUTICS Corp | ROTHBLATT MARTINE A | Director, Officer; Chairperson & CEO | Pharmaceutical Preparations | OPT+S | $547.49 | 9,500 | $5,201,109 | 40,513 | -19.0% |
| 2026-06-09 20:49 | 2026-06-05 | ELVN | Enliven Therapeutics, Inc. | Kunkel Lori Anne | Director | Pharmaceutical Preparations | SALE | $34.54 | 10,000 | $345,351 | 51,884 | -16.2% |
| 2026-06-09 20:24 | 2026-06-05 | VRTX | VERTEX PHARMACEUTICALS INC / MA | Bozic Carmen | Officer; EVP and CMO | Pharmaceutical Preparations | SALE | $450.00 | 1,745 | $785,250 | 21,015 | -7.7% |
| 2026-06-09 17:59 | 2026-06-08 | URGN | UroGen Pharma Ltd. | Schoenberg Mark | Officer; Chief Medical Officer | Pharmaceutical Preparations | OPT+S | $27.30 | 5,222 | $142,561 | 139,763 | -3.6% |
| 2026-06-09 16:04 | 2026-06-05 | AIMD | Ainos, Inc. | chiang yao-chung | Director | Pharmaceutical Preparations | BUY | $2.05 | 3,500 | $7,175 | 11,279 | +45.0% |
| 2026-06-08 20:36 | 2026-06-04 | KROS | Keros Therapeutics, Inc. | Knowles Julius | Director | Pharmaceutical Preparations | SALE | $10.73 | 2,625 | $28,166 | 10,958 | -19.3% |
| 2026-06-09 01:05 | 2026-06-08 | CYRX | Cryoport, Inc. | Mandalam Ramkumar | Director | Pharmaceutical Preparations | SALE | $15.44 | 23,214 | $358,452 | 67,894 | -25.5% |
| 2026-06-09 01:11 | 2026-06-04 | CYRX | Cryoport, Inc. | STEFANOVICH ROBERT | Officer; Chief Financial Officer | Pharmaceutical Preparations | SALE | $16.27 | 169,427 | $2,756,984 | 109,850 | -60.7% |
| 2026-06-09 01:19 | 2026-06-05 | XENE | Xenon Pharmaceuticals Inc. | Cannon Gillian | Director | Pharmaceutical Preparations | SALE | $53.14 | 1,190 | $63,237 | 1,455 | -45.0% |
| 2026-06-09 01:19 | 2026-06-05 | XENE | Xenon Pharmaceuticals Inc. | PATOU GARY | Director | Pharmaceutical Preparations | SALE | $53.14 | 1,322 | $70,251 | 24,896 | -5.0% |
| 2026-06-09 00:27 | 2026-06-04 | ADPT | Adaptive Biotechnologies Corp | BOBULSKY SUSAN | Officer; Chief Commercial Officer, MRD | Biological Products, (No Diagnostic Substances) | SALE | $18.00 | 11,000 | $198,000 | 416,775 | -2.6% |
| 2026-06-09 00:29 | 2026-06-04 | ADPT | Adaptive Biotechnologies Corp | LO FRANCIS | Officer; Chief People Officer | Biological Products, (No Diagnostic Substances) | OPT+S | $17.49 | 39,741 | $695,070 | 250,934 | -13.7% |
| 2026-06-08 23:02 | 2026-02-13 | CING | Cingulate Inc. | Hargroves Thomas Jeffrey | Director | Pharmaceutical Preparations | BUY | $5.04 | 97,276 | $490,271 | 97,468 | +50,664.6% |
| 2026-06-08 22:07 | 2026-06-04 | NBIX | NEUROCRINE BIOSCIENCES INC | Norwalk Leslie V | Director | Biological Products, (No Diagnostic Substances) | SALE | $168.06 | 1,250 | $210,072 | 2,838 | -30.6% |
| 2026-06-08 22:10 | 2026-06-08 | USNA | USANA HEALTH SCIENCES INC | Jones Paul A. | Officer; CHIEF PEOPLE OFFICER | Medicinal Chemicals & Botanical Products | SALE | $18.50 | 5,561 | $102,879 | 0 | -100.0% |
| 2026-06-08 22:13 | 2026-06-04 | HOWL | Werewolf Therapeutics, Inc. | EVNIN LUKE | Director | Pharmaceutical Preparations | SALE | $0.41 | 105,565 | $43,028 | 377,211 | -21.9% |
| 2026-06-08 22:19 | 2026-06-05 | ADTX | Aditxt, Inc. | HRT FINANCIAL LP | 10% owner | Pharmaceutical Preparations | SALE | $0.06 | 735,462 | $45,599 | 0 | -100.0% |
| 2026-06-08 22:19 | 2026-06-04 | ADTX | Aditxt, Inc. | HRT FINANCIAL LP | 10% owner | Pharmaceutical Preparations | BUY | $0.08 | 843,622 | $64,115 | 505,302 | +100.0% |
| 2026-06-08 22:01 | 2026-06-04 | BBIO | BridgeBio Pharma, Inc. | Kumar Neil | Director, Officer; Chief Executive Officer | Pharmaceutical Preparations | SALE | $67.67 | 80,000 | $5,413,288 | 4,318,447 | -1.8% |
| 2026-06-08 20:37 | 2026-06-04 | KROS | Keros Therapeutics, Inc. | Farzan Nima | Director | Pharmaceutical Preparations | SALE | $10.73 | 2,625 | $28,166 | 9,767 | -21.2% |
| 2026-06-08 20:41 | 2026-06-04 | LQDA | Liquidia Corp | Manning Paul B | Director | Pharmaceutical Preparations | SALE | $63.91 | 200,000 | $12,782,060 | 798,335 | -20.0% |
| 2026-06-08 20:30 | 2026-06-04 | LQDA | Liquidia Corp | Bloch Stephen M | Director | Pharmaceutical Preparations | SALE | $64.95 | 84,800 | $5,507,785 | 1,785,242 | -4.5% |
| 2026-06-08 20:33 | 2026-06-05 | UTHR | UNITED THERAPEUTICS Corp | ROTHBLATT MARTINE A | Director, Officer; Chairperson & CEO | Pharmaceutical Preparations | OPT+S | $547.62 | 9,500 | $5,202,437 | 40,513 | -19.0% |
| 2026-06-08 20:34 | 2026-06-04 | MRNA | Moderna, Inc. | Klinger Shannon Thyme | Officer; Chief Legal Officer | Biological Products, (No Diagnostic Substances) | OPT+S | $50.00 | 3,471 | $173,550 | 67,468 | -4.9% |
Strategic Signal Filtering
Our screener allows you to cut through the noise of routine stock grants and small trades. By focusing on high-value transactions from C-suite executives (CEO/CFO), you can identify where the "Smart Money" is being deployed with maximum conviction.
Investing Without Illusions
Insider data is not a magic wand, but it is the most honest indicator available. While insiders sell for many reasons (taxes, personal needs), they generally buy for only one: they believe the stock price is undervalued. We provide the tools to track these skin-in-the-game moves.
UNDERSTANDING THE DATA
FILING DATE: The date and time when the transaction was reported to the SEC. This is when the public first receives the information.
TRADE DATE: The actual day the insider executed the purchase or sale in the market.
INDUSTRY: The specific market sector the company operates in. Useful for identifying broader institutional capital flows across sectors.
OWNED AFTER: The total number of shares held by the insider following the transaction. This highlights the insider's remaining conviction in the company.
CHANGE %: The percentage increase or decrease of the insider's total position. Large percentage changes often carry more weight than the dollar amount alone.
TRADE TYPES DEFINITIONS
BUY: An open market purchase. Typically indicates an insider's belief that the stock is undervalued or poised for growth.
SELL: An open market sale. While often used for diversification or liquidity, large or unexpected sales can be a warning signal.
OPT+S (OPTION EXERCISE & SALE): This occurs when an insider exercises their stock options and sells them immediately. Often part of a structured compensation plan.